Reply to Juan Gómez Rivas, Giorgio Gandaglia, and Francesco Montorsi’s Letter to the Editor re: Neal D. Shore, Joseph Renzulli, Neil E. Fleshner, et al. Enzalutamide Monotherapy vs Active Surveillance in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol 2022;8:1128–36
-
Published:2022-12
Issue:
Volume:46
Page:145-146
-
ISSN:2666-1683
-
Container-title:European Urology Open Science
-
language:en
-
Short-container-title:European Urology Open Science
Funder
Astellas Pharma US
Pfizer